Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Vurdering av den reelle verdens sikkerhet og effektivitet hos deltakere med spinal muskelatrofi behandlet med intratekal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): En amerikansk pragmatisk multikenterstudie (STREAM)

28. oktober 2026 oppdatert av: Novartis Pharmaceuticals

Onasemnogene Abeparvovec: Vurdering av den reelle verdens sikkerhet og effektivitet hos deltakere med spinal muskelatrofi behandlet med intratekal Onasemnogene Abeparvovec-brve (ITVISMA®): En amerikansk pragmatisk multicenter-studie (STREAM)

The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

STREAM is a prospective, multicentre cohort study that will follow U.S. participants with genetically confirmed SMA who receive a single, intrathecal dose of onasemnogene abeparvovec-brve. All eligible participants are enrolled prior to therapeutic injection. No randomisation, blinding, or placebo control is employed; instead, each participant acts as his or her own baseline comparator. This study will use an exploratory external cohort of patients matched by age, clinical characteristics, treatment history and availability of at least 1 year of pre-treatment medical history. This patient cohort will be based on a database of retrospectively collected electronic medical records data and will be used descriptively to contextualize study outcomes. Bias is minimised through pre-specified endpoints, uniform rater training on motor-function scales, and a detailed statistical analysis plan that stipulates handling of missing data and intercurrent events in advance.

Studietype

Intervensjonell

Registrering (Antatt)

36

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Novartis Pharmaceuticals

Studiesteder

    • Arkansas
      • Little Rock, Arkansas, Forente stater, 208833
        • Rekruttering
        • Arkansas Children's Hospital
        • Hovedetterforsker:
          • Aravindhan Veerapandiyan
        • Ta kontakt med:
          • Buffy Gofforth
          • Telefonnummer: (501) 364-1591
    • California
      • Stanford, California, Forente stater, 94305-5235
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Boston Childrens Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Leslie Hayes
    • New York
      • New York, New York, Forente stater, 10032
        • Rekruttering
        • Columbia University Medical Center
        • Hovedetterforsker:
          • Claudia Chiriboga
        • Ta kontakt med:
    • Ohio
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • Ohio State University Medical Center
        • Hovedetterforsker:
          • Bakri Elsheikh
        • Ta kontakt med:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 209277
        • Rekruttering
        • University of Pennsylvania
        • Hovedetterforsker:
          • Lauren Elman
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år til 100 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

A participant will be enrolled in STREAM only if all the following conditions are met:

  • The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).

  • He or she is ≥ 2 years of age on the day of the intrathecal injection.

  • The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.

  • One of the following functional categories applies at screening:

    1. independently ambulatory child/adolescent 2 - <18 years; or
    2. independently ambulatory adult (≥ 18 years).
    3. non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
  • At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.

Key Exclusion Criteria:

A participant will be excluded if any of the following conditions apply:

  • Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
  • An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
  • Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
  • Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
  • Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.

Other protocol inclusion, exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Onasemnogene Abeparvovec-brve

Participants with spinal muscular atrophy, including:

  • independently ambulatory children/adolescents (≥ 2 years to < 18 years);
  • independently ambulatory adults (≥ 18 years);
  • Non-ambulatory adults (≥ 18 years)

administered once via lumbar puncture with systemic corticosteroid prophylaxis per label.

Andre navn:
  • (ITVISMA®)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in HFMSE for independently ambulatory participants
Tidsramme: Baseline, 6, 12, 18 and 24 months

The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression.

The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Change from baseline in RULM for non-ambulatory (including walkers with assistance) participants
Tidsramme: Baseline, 6, 12, 18 and 24 months

The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-ambulatory (including walkers with assistance) individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: up to 5 years

Incidence of AEs and SAEs, including changes in laboratory tests and procedure-related events qualifying and reported as AEs.

up to 5 years
Modified SMA Functional Rating Scale (SMA-FRS) for independently ambulatory participants (≥ 18 years of age) and non-ambulatory particpants
Tidsramme: Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5

Modified Spinal Muscular Atrophy Functional Rating Scale (SMAFRS): Ten items address questions related to eating, upper extremity dressing, lower extremity dressing, grooming, bathing, toileting, turning in bed and adjusting bed clothes, transfers, walking, and climbing stairs. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) for independently ambulatory participants (<18 years of age)
Tidsramme: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

The Assessment of Caregiver Experience with Neuromuscular Disease (ACEND): quantifies caregivers' perceptions of function and quality of life pertaining to time, finance and emotion. The ACEND was developed and validated to specifically assess caregiver impact experienced by raising children severely affected by neuromuscular diseases. While specifically developed for application to caregivers of patients undergoing orthopedic surgery, it has application to those with SMA. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Subgroup outcomes: Hammersmith Functional Motor Scale Expanded (HFMSE)
Tidsramme: Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The HFMSE is a validated SMA specific assessment to give objective information on motor ability and clinical progression. Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Subgroup outcomes: Revised Upper Limb Module (RULM)
Tidsramme: Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-independent ambulatory individuals with SMA. Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months
Frequency of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Tidsramme: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Duration of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Tidsramme: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Cobb angle
Tidsramme: Baseline, up to 24 months

Assessment of scoliosis progression as a disease-progression marker.

Baseline, up to 24 months
Daily hours of respiratory support (none, non-invasive ventilation, invasive ventilation)
Tidsramme: Baseline, up to 24 months

Assessment of respiratory function as a disease-progression marker.

Baseline, up to 24 months
Joint-range limitation measured by goniometer
Tidsramme: Baseline, up to 24 months

Assessment of evolution of joint contractures as a disease-progression marker.

Baseline, up to 24 months
Nutritional-support category (oral, gastrostomy feeds, total parenteral nutrition)
Tidsramme: Baseline, up to 24 months

Assessment of nutrition status as a disease-progression marker.

Baseline, up to 24 months
6-Minute Walk Test (6MWT) for ambulatory patients
Tidsramme: Baseline, Months 6, 12, 18, and 24

To assess disease-progression markers. 6MWT: distance in metres; greater distance indicates better ambulatory capacity.

Baseline, Months 6, 12, 18, and 24

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. august 2026

Primær fullføring (Antatt)

3. mai 2032

Studiet fullført (Antatt)

30. juni 2032

Datoer for studieregistrering

Først innsendt

26. februar 2026

Først innsendt som oppfylte QC-kriteriene

26. februar 2026

Først lagt ut (Faktiske)

4. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • COAV101B1US01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .